CN102294013B - 一种促肝细胞生长素,其制剂及应用 - Google Patents
一种促肝细胞生长素,其制剂及应用 Download PDFInfo
- Publication number
- CN102294013B CN102294013B CN201110264733.2A CN201110264733A CN102294013B CN 102294013 B CN102294013 B CN 102294013B CN 201110264733 A CN201110264733 A CN 201110264733A CN 102294013 B CN102294013 B CN 102294013B
- Authority
- CN
- China
- Prior art keywords
- hepatocyte growth
- promoting factors
- promoting
- speed
- promoting factor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000003494 hepatocyte Anatomy 0.000 title claims abstract description 100
- 238000002360 preparation method Methods 0.000 claims abstract description 31
- 150000001413 amino acids Chemical class 0.000 claims abstract description 21
- 238000012360 testing method Methods 0.000 claims abstract description 17
- 238000004458 analytical method Methods 0.000 claims abstract description 13
- 210000004027 cell Anatomy 0.000 claims abstract description 12
- 235000013619 trace mineral Nutrition 0.000 claims abstract description 11
- 239000011573 trace mineral Substances 0.000 claims abstract description 11
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 7
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 7
- 238000003556 assay Methods 0.000 claims abstract description 6
- 238000000338 in vitro Methods 0.000 claims abstract description 6
- 230000035755 proliferation Effects 0.000 claims abstract description 3
- 238000000034 method Methods 0.000 claims description 41
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 37
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 27
- 239000007791 liquid phase Substances 0.000 claims description 23
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 claims description 13
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 claims description 13
- 239000012071 phase Substances 0.000 claims description 10
- 230000001737 promoting effect Effects 0.000 claims description 10
- 239000000843 powder Substances 0.000 claims description 6
- 230000014759 maintenance of location Effects 0.000 claims description 4
- QEVHRUUCFGRFIF-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C(C5=CC=C(OC)C=C5N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 QEVHRUUCFGRFIF-MDEJGZGSSA-N 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 11
- 239000013543 active substance Substances 0.000 abstract description 3
- 238000004128 high performance liquid chromatography Methods 0.000 abstract description 2
- -1 methyl thiazolyl Chemical group 0.000 abstract description 2
- 239000000243 solution Substances 0.000 description 44
- 239000012510 hollow fiber Substances 0.000 description 30
- 239000012528 membrane Substances 0.000 description 28
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 27
- 210000004185 liver Anatomy 0.000 description 21
- 230000008569 process Effects 0.000 description 17
- 238000010438 heat treatment Methods 0.000 description 16
- 229910001220 stainless steel Inorganic materials 0.000 description 16
- 239000010935 stainless steel Substances 0.000 description 16
- 241000282894 Sus scrofa domesticus Species 0.000 description 15
- 238000007710 freezing Methods 0.000 description 14
- 238000010257 thawing Methods 0.000 description 13
- 238000000108 ultra-filtration Methods 0.000 description 13
- 239000000470 constituent Substances 0.000 description 12
- 239000004744 fabric Substances 0.000 description 12
- 230000008014 freezing Effects 0.000 description 12
- 239000000203 mixture Substances 0.000 description 12
- 238000010792 warming Methods 0.000 description 12
- 238000001914 filtration Methods 0.000 description 11
- 238000012545 processing Methods 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 10
- 239000006228 supernatant Substances 0.000 description 10
- 235000013399 edible fruits Nutrition 0.000 description 9
- 210000003195 fascia Anatomy 0.000 description 9
- 239000000706 filtrate Substances 0.000 description 9
- 238000004321 preservation Methods 0.000 description 9
- 239000002994 raw material Substances 0.000 description 9
- 238000001223 reverse osmosis Methods 0.000 description 9
- 239000008215 water for injection Substances 0.000 description 9
- 239000011575 calcium Substances 0.000 description 8
- 239000011734 sodium Substances 0.000 description 8
- 239000012531 culture fluid Substances 0.000 description 7
- 239000000126 substance Substances 0.000 description 6
- 238000000605 extraction Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 239000012980 RPMI-1640 medium Substances 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 230000005524 hole trap Effects 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 244000309466 calf Species 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229940000406 drug candidate Drugs 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000003777 experimental drug Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 206010008909 Chronic Hepatitis Diseases 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 206010019755 Hepatitis chronic active Diseases 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 229930192334 Auxin Natural products 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010019668 Hepatic fibrosis Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000002363 auxin Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 238000009640 blood culture Methods 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229940087511 calcium disodium versenate Drugs 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 210000005161 hepatic lobe Anatomy 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- SEOVTRFCIGRIMH-UHFFFAOYSA-N indole-3-acetic acid Chemical compound C1=CC=C2C(CC(=O)O)=CNC2=C1 SEOVTRFCIGRIMH-UHFFFAOYSA-N 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Landscapes
- Peptides Or Proteins (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110264733.2A CN102294013B (zh) | 2011-09-08 | 2011-09-08 | 一种促肝细胞生长素,其制剂及应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110264733.2A CN102294013B (zh) | 2011-09-08 | 2011-09-08 | 一种促肝细胞生长素,其制剂及应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102294013A CN102294013A (zh) | 2011-12-28 |
CN102294013B true CN102294013B (zh) | 2014-01-29 |
Family
ID=45354846
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201110264733.2A Active CN102294013B (zh) | 2011-09-08 | 2011-09-08 | 一种促肝细胞生长素,其制剂及应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102294013B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108676769B (zh) * | 2018-04-24 | 2022-09-23 | 武汉仝干医疗科技股份有限公司 | 一种促进肝细胞生长的无纺布支架材料及其制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1533806A (zh) * | 2003-03-28 | 2004-10-06 | 威海赛洛金药业有限公司 | 促肝细胞生长素注射液及制备方法和应用 |
CN1903357A (zh) * | 2005-07-27 | 2007-01-31 | 武汉同源药业有限公司 | 注射用肝水解肽及其制备方法 |
CN1907262A (zh) * | 2006-08-02 | 2007-02-07 | 沈阳斯佳科技发展有限公司 | 促肝细胞生长素水针制剂的制备方法 |
-
2011
- 2011-09-08 CN CN201110264733.2A patent/CN102294013B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1533806A (zh) * | 2003-03-28 | 2004-10-06 | 威海赛洛金药业有限公司 | 促肝细胞生长素注射液及制备方法和应用 |
CN1903357A (zh) * | 2005-07-27 | 2007-01-31 | 武汉同源药业有限公司 | 注射用肝水解肽及其制备方法 |
CN1907262A (zh) * | 2006-08-02 | 2007-02-07 | 沈阳斯佳科技发展有限公司 | 促肝细胞生长素水针制剂的制备方法 |
Non-Patent Citations (2)
Title |
---|
徐明红等.肝细胞生长素研究进展.《广东药学院学报》.1995,第11卷(第1期), |
肝细胞生长素研究进展;徐明红等;《广东药学院学报》;19951231;第11卷(第1期);39-41 * |
Also Published As
Publication number | Publication date |
---|---|
CN102294013A (zh) | 2011-12-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10414795B2 (en) | Techniques of preparing collagen active peptides | |
JP4420470B2 (ja) | あわび多糖類抽出方法 | |
KR101717266B1 (ko) | 복합 콜라겐 스폰지 및 그의 제조방법 | |
CN104232718B (zh) | 铁皮石斛抗肿瘤多肽的制备方法及应用 | |
CN108610274B (zh) | 一组环γ-聚谷氨酸系列分子及其制备方法和应用 | |
CA2728358C (en) | Storage-stable, functionally intact fibrinogen | |
CN108118077A (zh) | 一种酶法水解三文鱼胶原制备抗氧化肽与抗冻肽的工艺 | |
CN102188692B (zh) | 一种骨肽组合物及其制剂、制备方法和应用 | |
CN101628025B (zh) | 包含鹿骨提取物和甜瓜籽提取物的药物组合物 | |
CN102294014B (zh) | 一种促肝细胞生长素,其制剂和用途 | |
CN101020715B (zh) | 鹿茸神经生长因子(deer ngf)提取及其制备方法 | |
CN104163847B (zh) | 蝇蛆活性蛋白肽的制备方法与所制备的蝇蛆活性蛋白肽及其用途 | |
CN107751697A (zh) | 小球藻精藻蓝蛋白功能饮品制备方法 | |
CN102172257A (zh) | 一种超细丝素肽粉的制作方法 | |
CN102294013B (zh) | 一种促肝细胞生长素,其制剂及应用 | |
CN106086139A (zh) | 一种利用淡水鱼头蛋白酶解制备鱼头多肽的方法 | |
CN104524603B (zh) | 可被生物机体吸收的止血生物制品/生物材料的病毒去除/灭活方法 | |
CN100594930C (zh) | 以垂体前叶肾上腺皮质提取物为主要成份的组合药物及其制备方法和用途 | |
CN107595924B (zh) | 一种骨瓜提取物注射液制备方法及相应的药物组合物 | |
CN109943554A (zh) | 一种从蛇毒中提取凝血因子x激活剂的方法 | |
CN106518960A (zh) | 完全物理法制备动物脏器小分子多肽的方法 | |
CN106474455A (zh) | 一种茶叶多肽在制备抗ii型糖尿病药物或保健品中的应用 | |
CN101081865B (zh) | 鹿茸促生长释放因子(deer ghrf)提取及其制备方法 | |
CN106474461B (zh) | 制备冻干人凝血酶的方法 | |
CN110551789A (zh) | 一种具有成骨活性的贻贝肽冻干粉的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: GUANGZHOU VANKING PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: HOSPITAL NO.458 OF P.L.A.;HOSPITAL NO.458 OF P.L.A. Effective date: 20150612 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20150612 Address after: 510760 Guangdong city of Guangzhou Province Economic and Technological Development Zone East Road No. 6 self building Patentee after: GUANGZHOU YIPINHONG PHARMACEUTICAL Co.,Ltd. Address before: 510600 No. 801 Dongfeng East Road, Guangdong, Guangzhou Patentee before: 458TH HOSPITAL OF PLA |
|
CB03 | Change of inventor or designer information |
Inventor after: Li Hanxiong Inventor after: Sun Xiangping Inventor after: Chen Guangming Inventor after: Zhang Yijun Inventor after: Yang Fuqiang Inventor after: Zhang Haisong Inventor after: Chen Yangshu Inventor before: Kong Xiangping Inventor before: Chen Guangming Inventor before: Zhang Yijun Inventor before: Yang Fuqiang Inventor before: Zhang Haisong Inventor before: Chen Yangshu |
|
CB03 | Change of inventor or designer information | ||
TR01 | Transfer of patent right |
Effective date of registration: 20221116 Address after: No.6 Dongbo Road, East District, Guangzhou Economic and Technological Development Zone, Guangdong 510000 Patentee after: GUANGZHOU YIPINHONG PHARMACEUTICAL Co.,Ltd. Patentee after: GUANGDONG ZERUI PHARMACEUTICAL Co.,Ltd. Patentee after: Guangzhou Lianrui Pharmaceutical Co.,Ltd. Patentee after: Guangzhou Runlin Pharmaceutical Technology Co.,Ltd. Patentee after: Euphorbia Biological Medicine Co.,Ltd. Address before: Building 1, No. 6, Dongbo Road, Guangzhou Economic and Technological Development Zone, Guangdong 510760 Patentee before: GUANGZHOU YIPINHONG PHARMACEUTICAL Co.,Ltd. |
|
TR01 | Transfer of patent right |